Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jumper is a London-based biotechnology company specializing in generative artificial intelligence for de novo protein design. Founded by Simon Kohl, a former lead researcher on the AlphaFold team at Google DeepMind, the company develops advanced machine learning models to program biology and create entirely new therapeutic molecules, including antibodies and enzymes. Jumper aims to move protein engineering further into the computational domain, enabling the design of proteins with specific functions that do not exist in nature. The company's platform is designed to accelerate drug discovery by providing highly accurate, end-to-end AI workflows for molecular engineering.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jumper.